Genetic susceptibility to radiogenic cancer in humans

Health Physics

Volumn 95, Issue 5, 2008, Pages 677-686

  Allan, James M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Genetic effects, radiation; Health effects; National Council on Radiation Protection and Measurements

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; ALLELE; ATAXIA TELANGIECTASIA; AUTOSOMAL RECESSIVE DISORDER; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CYTOTOXICITY; ENVIRONMENTAL EXPOSURE; FAMILIAL CANCER; FANCONI ANEMIA; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HUMAN; INHERITANCE; IONIZING RADIATION; NEUROFIBROMATOSIS; NIJMEGEN BREAKAGE SYNDROME; NONHUMAN; OVARY CANCER; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION DOSE; RADIATION EXPOSURE; RETINOBLASTOMA; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; ARTICLE; CHROMOSOME MAP; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETICS; RADIATION INJURY; RECESSIVE GENE; RISK FACTOR; SECOND CANCER; SURVIVOR; SYNDROME;

ANIMALIA;

CHROMOSOME MAPPING; GENES, RECESSIVE; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PHENOTYPE; RISK FACTORS; SURVIVORS; SYNDROME;

EID: 56149107476     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000326339.06405.ea     Document Type: Conference Paper

References (88)

1. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term causespecific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439; 2003.
2. Allan JM, Rabkin CS. Genetic susceptibility to iatrogenic malignancy. Pharmacogenomics 6:615- 628; 2005.
3. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5:943-955; 2005.
4. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, van't Veer L, van Leeuwen FE, Goldgar DE. Effect of chest x-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 24:3361-3366; 2006. (Pubitemid 46638890)
5. Angele S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gerard JP, Hall J. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 63:8717-8725; 2003. (Pubitemid 38064049)
6. Backlund MG, Trasti SL, Backlund DC, Cressman VL, Godfrey V, Koller BH. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res 61:6577-6582; 2001. (Pubitemid 32783267)
7. Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 82:998; 2000. (Pubitemid 30085257)
8. Bielas JH, Heddle JA. Proliferation is necessary for both repair and mutation in transgenic mouse cells. Proceedings National Academy of Sciences 97:11391-11396; 2000.
9. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621- 4628; 2001. (Pubitemid 32762434)
10. Boice JD Jr, Preston D, Davis FG, Monson RR. Frequent chest x-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res 125:214 -222; 1991.
11. Boyle JM, Mitchell EL, Greaves MJ, Roberts SA, Tricker K, Burt E, Varley JM, Birch JM, Scott D. Chromosome instability is a predominant trait of fibroblasts from Li- Fraumeni families. B J Cancer 77:2181-2192; 1998. (Pubitemid 28263939)
12. Boyle JM, Spreadborough AR, Greaves MJ, Birch JM, Varley JM, Scott D. Delayed chromosome changes in gammairradiated normal and Li-Fraumeni fibroblasts. Radiat Res 157:158 -165; 2002. (Pubitemid 34101367)
13. Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van't Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen F, van't Veer LJ. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol 76:693- 698; 2000.
14. Calaf GM, Hei TK. Establishment of a radiation- and estrogeninduced breast cancer model. Carcinogenesis 21:769 -776; 2000.
15. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679; 1998. (Pubitemid 28435584)
16. Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 8:337-348; 2005. (Pubitemid 41443418)
17. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443:214 -217; 2006. (Pubitemid 44387609)
18. Chrzanowska KH, Piekutowska-Abramczuk D, Popowska E, Gladkowska-Dura M, Maldyk J, Syczewska M, Krajewska- Walasek M, Goryluk-Kozakiewicz B, Bubala H, Gadomski A, Gaworczyk A, Kazanowska B, Koltan A, Kuzmicz M, Luszawska-Kutrzeba T, Maciejka-Kapuscinska L, Stolarska M, Stefanska K, Sznurkowska K, Wakulinska A, Wieczorek M, Szczepanski T, Kowalczyk J. Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies. Int J Cancer 118:1269 -1274; 2006. (Pubitemid 43185616)
19. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593- 604; 2001. (Pubitemid 32201953)
20. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 11:90 -92; 1995.
21. Digweed M, Reis A, Sperling K. Nijmegen breakage syndrome: consequences of defective DNA double strand break repair. Bioessays 21:649-656; 1999. (Pubitemid 29384446)
22. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2:507-514; 2002. (Pubitemid 41043955)
23. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20:3484 -3494; 2002.
24. Drabek J, Hajduch M, Gojova L, Weigl E, Mihal V. Frequency of 657del(5) mutation of the NBS1 gene in the Czech population by polymerase chain reaction with sequence specific primers. Cancer Genet Cytogenet 138:157-159; 2002.
25. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661- 671; 1986.
26. Dumon-Jones V, Frappart PO, Tong WM, Sajithlal G, Hulla W, Schmid G, Herceg Z, Digweed M, Wang ZQ. Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis. Cancer Res 63:7263-7269; 2003. (Pubitemid 37413466)
27. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841- 846; 1992.
28. Feig SA, Hendrick RE. Radiation risk from screening mammography of women aged 40-49 years. J Natl Cancer Ins Monogr 22:119 -124; 1997.
29. Feuerhake F, Sigg W, Hofter EA, Unterberger P, Welsch U. Cell proliferation, apoptosis, and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 77:37- 48; 2003. (Pubitemid 36182915)
30. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462; 1995.
31. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 59:1731s-1735s; 1999.
32. Gilbert ES, Stovall M, Gospodarowicz M, van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van't Veer MB, Fraumeni JF, Boice JD Jr, Clarke EA, Travis LB. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 159:161-173; 2003.
33. Goldfrank D, Chuai S, Bernstein JL, Ramon YC, Lee JB, Alonso MC, Diez O, Baiget M, Kauff ND, Offit K, Robson M. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 15:2311-2313; 2006. (Pubitemid 44877062)
34. Gutierrez-Enriquez S, Fernet M, Dork T, Bremer M, Lauge A, Stoppa-Lyonnet D, Moullan N, Angele S, Hall J. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 40:109 -119; 2004. (Pubitemid 38579879)
35. Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, van't Veer M, Storm H, Pukkala E, Stovall M, Curtis RE, Allan JM, Boice JD, Travis LB. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 106:3358 -3365; 2005.
36. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90:606-611; 1998. (Pubitemid 28204804)
37. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8(Suppl 1):115-118; 1997.
38. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609; 2002. (Pubitemid 34815345)
39. Huang L, Snyder AR, Morgan WF. Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene 22:5848 -5854; 2003. (Pubitemid 37176705)
40. Kastan MB, Lim DS, Kim ST, Yang D. ATM-a key determinant of multiple cellular responses to irradiation. Acta Oncol 40:686-688; 2001. (Pubitemid 33081975)
41. Kazakov VS, Demidchik EP, Astakhova LN. Thyroid cancer after Chernobyl. Nature 359:21-22; 1992.
42. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 92:795- 802; 2000.
43. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23:2272- 2279; 2005. (Pubitemid 46218720)
44. Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99:24 -31; 2007.
45. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proceed Natl Acad Sciences 89:7491-7495; 1992.
46. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3:122-126; 1993. (Pubitemid 23079793)
47. Li X, Dumont P, Della PA, Shetler C, Murphy ME. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 280:24245-24251; 2005. (Pubitemid 40884914)
48. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int Cancer 96:238 -242; 2001. (Pubitemid 33081228)
49. Lohmann DR. RB1 gene mutations in retinoblastoma. Hum Mutat 14:283-288; 1999.
50. Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, Lange BJ, Shannon KM. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79:1438 -1446; 1997. (Pubitemid 27143252)
51. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, van't Veer MB, Curtis RE, Holowaty EJ, Andersson M, Wiklund T, Gospodarowicz M, Travis LB. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 18:2435-2443; 2000.
52. Moll AC, Kuik DJ, Bouter LM, den Otter W, Bezemer PD, Koten JW, Imhof SM, Kuyt BP, Tan KE. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995. Br J Ophthalmol 81:559 -562; 1997.
53. Narisawa T, Wong CQ, Weisburger JH. Large bowel carcinoma in strain-2 guinea pigs by intrarectal instillation of N-methyl-N'-nitro-n-nitrosoguanidine. Gann 67:41- 46; 1976.
54. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2:113-123; 2002.
55. Narod S, Lubinski J. Re: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:1552; 2003. (Pubitemid 37322100)
56. Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 7:402- 406; 2006.
57. Neubauer S, Arutyunyan R, Stumm M, Dork T, Bendix R, Bremer M, Varon R, Sauer R, Gebhart E. Radiosensitivity of ataxia telangiectasia and Nijmegen breakage syndrome homozygotes and heterozygotes as determined by threecolor FISH chromosome painting. Radiat Res 157:312-321; 2002. (Pubitemid 34263845)
58. Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer 86:2575-2582; 1999.
59. Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L. Heterozygous germline ATM mutations do not contribute to radiationassociated malignancies after Hodgkin's disease. J Clin Oncol 17:1259; 1999. (Pubitemid 29162952)
60. Nutting C, Camplejohn RS, Gilchrist R, Tait D, Blake P, Knee G, Yao WQ, Ross G, Fisher C, Eeles R. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 12:300 -304; 2000.
61. Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Pierce HH, Kauff ND, Einat P, Jhanwar S, Satagopan JM, Oddoux C, Ellis N, Skaliter R, Yahalom J. Rare variants of ATM and risk for Hodgkin's disease and radiationassociated breast cancers. Clin Cancer Res 8:3813-3819; 2002. (Pubitemid 35424774)
62. Pandita TK, Hittelman WN. Increased initial levels of chromosome damage and heterogeneous chromosome repair in ataxia telangiectasia heterozygote cells. Mutat Res 310:1- 13; 1994.
63. Parshad R, Price FM, Pirollo KF, Chang EH, Sanford KK. Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat Res 136:236 -240; 1993. (Pubitemid 2027781)
64. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22:5784 -5791; 2003.
65. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259 -277; 1995.
66. Rubinstein WS. Hereditary breast cancer in Jews. Fam Cancer 3:249 -257; 2004.
67. Saad AG, Kumar S, Ron E, Lubin JH, Stanek J, Bove KE, Nikiforov YE. Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab 91:2672-2677; 2006. (Pubitemid 44024635)
68. Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer 27:124 -129; 2000. (Pubitemid 30030309)
69. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597- 601; 1994. (Pubitemid 24065793)
70. Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, Evans DG. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24:2570 -2575; 2006. (Pubitemid 46630636)
71. Singhal S, Birch JM, Kerr B, Lashford L, Evans DG. Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child 87:65-70; 2002. (Pubitemid 34753778)
72. Smilenov LB, Brenner DJ, Hall EJ. Modest increased sensitivity to radiation oncogenesis in ATM heterozygous versus wild-type mammalian cells. Cancer Res 61:5710 -5713; 2001.
73. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska D, Rubach M, Kosakowska E, Ruka W, Nowecki Z, Rutkowski P, Demkow T, Sadowska M, Bidzinski M, Gawrychowski K, Sperling K. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Intl J Cancer 111:67-71; 2004. (Pubitemid 38859284)
74. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107:4223- 4233; 2006. (Pubitemid 43801344)
75. Taylor M, Dehainault C, Desjardins L, Doz F, Levy C, Sastre X, Couturier J, Stoppa-Lyonnet D, Houdayer C, Gauthier- Villars M. Genotype-phenotype correlations in hereditary familial retinoblastoma. Hum Mutat 28:284 -293; 2007. (Pubitemid 46309978)
76. Travis LB, Curtis RE, Bennett WP, Hankey BF, Travis WD, Boice JD Jr. Lung cancer after Hodgkin's disease. J Natl Cancer Inst 87:1324 -1327; 1995.
77. Travis LB, Curtis RE, Boice JD Jr. Late effects of treatment for childhood Hodgkin's disease. N Engl J Med 335:352-353; 1996.
78. Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty E, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice JD Jr, Stovall M, Gilbert E. Treatmentassociated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171; 2000.
79. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94:182-192; 2002. (Pubitemid 34162752)
80. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465- 475; 2003.
81. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr, Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97:1428 -1437; 2005.
82. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. New York: UNSCEAR; Report to the General Assembly, with Annexes; Volume I; 2000.
83. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 87:1530 -1537; 1995.
84. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971-980; 2003.
85. Varon R, Seemanova E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska-Walasek M, Sykut- Cegielska J, Sperling K, Reis A. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 8:900 -902; 2000. (Pubitemid 30952810)
86. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2:543-549; 2002.
87. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278:1262- 1267; 1997.
88. Yannone SM, Roy S, Chan DW, Murphy MB, Huang S, Campisi J, Chen DJ. Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase. J Biol Chem 276:38242-38248; 2001. (Pubitemid 37384082)